Clinical trials: Acute Idiopathic Thrombocytopenic Purpura, open to volunteers
Immune Thrombocytopenia (ITP), Acute Ischemic Stroke
Longitudinal Cohort Study on Immune Thrombocytopenia Complicated With Acute Ischemic Stroke
Immune thrombocytopenia (ITP) is an acquired bleeding disorder mediated by immune-related platelet destruction and impaired platelet production.
- Trial name
- NCT07070193
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Immune Thrombocytopenia
Role of Acute Phase Proteins In Diagnosis of Immune Thrombocytopenia
Immune thrombocytopenia (ITP) are antibody-mediated disorders in which platelets are destroyed mainly through activating immunoglobulin (IgG) Fc receptors on phagocytes in the spleen and liver, eventually resulting in…
- Trial name
- NCT06715215
- Testing
- Acute phase proteins
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University
Immune Thrombocytopenic Purpura
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment.
- Trial name
- NYMC207 (NCT04323748)
- Testing
- rituxan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York Medical College